Yuichi Sakamori
Papers
1
Total Citations
6
H-Index
1
About
Yuichi Sakamori is a leading thoracic oncologist whose research focuses on the intersection of immunotherapy and surgical intervention for advanced non-small cell lung cancer (NSCLC). His major contribution lies in pioneering the concept of salvage surgery following immune checkpoint inhibitor (ICI) therapy for patients with initially unresectable disease. His landmark 2024 study, which has garnered 6 citations, systematically investigated the characteristics and outcomes of this novel treatment pathway, demonstrating that ICIs can successfully downstage tumors, enabling curative-intent resection where none was previously possible. This work has significant implications for expanding surgical candidacy and improving long-term survival in advanced NSCLC. Beyond this, Sakamori’s broader research portfolio explores optimizing multimodal treatment strategies, including the integration of targeted therapies and immunotherapies. His findings are increasingly cited in clinical guidelines, and he is recognized for bridging the gap between medical and surgical oncology, offering new hope to patients with historically poor prognoses. Through his rigorous outcomes analysis, Sakamori continues to shape the evolving landscape of lung cancer care.
Research Focus
Key Achievements
Top Papers
- 1